

Press release

Copenhagen, 18 May 2018

ViroGates accelerates commercialization of its products to aid emergency departments in prioritizing patient care.

ViroGates is a Danish medical technology company that develops and markets suPARnostic®, a proprietary blood-based test to assess patients in need of acute care. The prognostic power of the test helps medical professionals with informed decision making when admitting or discharging patients from the emergency department.

Following extensive clinical validation and clinical utility studies in more than 300,000 patients, suPARnostic® is now being tested in numerous clinical emergency departments across Europe. Following the first quarter of 2018, ViroGates has cooperation with ten emergency departments in Spain for the use of suPARnostic®. The hospitals are using the product in clinical settings to determine the value of using suPARnostic® when deciding upon admission to or discharge from the hospital. ViroGates has similar agreements with hospitals in Serbia, Romania, and Austria.

"Increased health care spending is a tremendous challenge for healthcare systems worldwide. ViroGates helps clinicians in their daily decision making in connection with admission or discharge of patients. This way, the healthcare systems can allocate resources more effectively. On a global scale, the total healthcare saving by using suPARnostic® could add up to as much as a double digit billion Euro figure. Our clinical customers use suPARnostic® to secure that discharge decisions are taken on an informed basis and to assure that only patients that are admitted do need urgent care " says CEO Jakob Knudsen.

The company has appointed Dr. Thomas Krarup as VP Sales & Marketing to lead the international clinical rollout. Initial focus is the European market which will be addressed through own sales force and by distributors. Thomas has previously worked in commercial roles at Radiometer Medical, Becton Dickinson, Roche, Exiqon and ChemoMetec.

ViroGates is currently evaluating different options for funding of its commercial execution.

About suPARnostic®

ViroGates' products monitor the level of inflammation and most, if not all, diseases have an underlying inflammatory component. suPARnostic® determines the presence and the severity of a disease as well as the prognosis of the individual patient.

suPARnostic® provides for a quick health assessment by analyzing the protein *soluble urokinase plasminogen activator receptor* (suPAR) in the blood in only 20 minutes via a simple blood sample. An elevated suPAR level is associated with the presence and severity of a broad range of acute and chronic conditions and is strongly associated with short term mortality. A low suPAR level is associated with a good prognosis and a low risk of short term mortality.

Contact

Jakob Knudsen, CEO
Tlf. +45 2226 1355
Email: jk@virogates.com